Results 231 to 239 of about 16,883 (239)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Journal of Infectious Diseases, 2014
Antonella Castagna, Franco Maggiolo, Anthony M Mills   +2 more
exaly  

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

Clinical Pharmacokinetics, 2013
Mackenzie L Cottrell, Angela D M Kashuba
exaly  

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

New England Journal of Medicine, 2013
Sharon L Walmsley, Franco Maggiolo
exaly  

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Clinical Infectious Diseases, 2022
exaly  

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Journal of Infectious Diseases, 2013
Joseph J Eron, Bonaventura Clotet, Adriano Lazzarin   +2 more
exaly  

Dolutegravir

Reactions Weekly, 2016
openaire   +1 more source

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

Lancet HIV,the, 2015
Bonaventura Clotet, Adriano Lazzarin, Matthias Cavassini   +2 more
exaly  

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet HIV,the, 2018
Indira Brar, Daniel Podzamczer
exaly  

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

HIV Medicine, 2017
exaly